355 TCR γδ+ TIL from patients with pancreatic cancer recognize autologous tumor cells restricted by CD1d Article Swipe
Joana R. Lérias
,
Patrícia António
,
Jéssica Kamiki
,
Rodrigo Eduardo
,
Sara Cascais
,
Bernardo Marinheiro
,
Eric de Sousa
,
Carolina Mendonça Gorgulho
,
Andreia Maia
,
Mireia Castillo-Martín
,
Markus W. Buechler
,
Carlos Carvalho
,
Antonio López-Beltrán
,
Sam Jeong
,
Ridong Chen
,
Markus Maeurer
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1136/jitc-2022-sitc2022.0355
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1136/jitc-2022-sitc2022.0355
Background Pancreatic cancer is the 7th leading cause of cancer-related deaths worldwide. Treatment options are still limited; immunotherapeutic approaches using tumor infiltrating lymphocytes (TIL) represent a viable option for PDAC patients. TILs from PDAC lesions will include αβ+ and γδ+ T-cells, that recognize tumor cells restricted by non-classical MHC I molecules.1,2 γδ+ TILs are generally associated with a more favorable prognosis3 and present promising candidates for adoptive cellular therapy as cellular products, or by cloning the molecular blueprint of cancer-specific TCRs that could be transferred into recipient immune cells. The study focused on the expansion of TIL containing TCR γδ+, molecular analysis of TCR γδ+ cells, and testing anti-tumor directed TIL specificity defined by IFN-gamma production upon NRLP3 pathway stimulation. Methods Freshly harvested tumor tissue was used to propagate TIL using cytokines in combination with an NRLP3 pathway activator for 2-3 weeks. γδ+ T-cell expansion and T-cell activation/exhaustion were tested by flow cytometry and autologous tumor recognition assays were performed using blocking mAbs and IFN-gamma as the biological readout; molecular recognition analysis was performed using synthetic peptides derived from tumor exome sequencing. TCR deep sequencing was performed in sorted TCR γδ+ TIL. Tumor infiltration by TCR γδ+ was gauged by immunohistochemistry and spatial transcriptomics. Results NRLP3 stimulation results in increased TCR γδ+ cells which – after sorting (>90% purity) – recognized autologous and allogeneic pancreatic cancer cells in a CD1d-restricted fashion defined by IFN-gamma production. TCR sequencing revealed a focused TCR repertoire with unusual Vgamma3 and Vgamma8 usage. NRLP3 stimulation increased the frequency of αβ+ T-cells against autologous tumor cells and mutant target epitopes defined by IFN-gamma production, abrogated with an NRLP3 inhibitor. Spatial transcriptomics revealed co-localization of CD1d and perforin+granzymeA+granzymeB γδ+ T-cells; TCR-sequencing of PDAC tissue and corresponding TIL exhibited an oligoclonal TCR repertoire. NRLP3 stimulation increased mRNA and protein expression of CXCL9 and CXCL10, which facilitates tissue invasion and favored CD1d restricted recognition of damaged mitochondria by γδ+ T-cells. Conclusions NRLP3 pathway stimulation increased tumor-reactive and mutant epitope specific TILs, increased expression of chemokines facilitating tissue invasion and expansion of γδ+ TIL engaged in surveillance of damaged mitochondria. This allows a clinically relevant expansion of TIL for patients with PDAC that recognized tumor associated antigens restricted by classical and non-classical MHC molecules. CD1d restricted and tumor-reactive γδ TCRs can be used as blueprints for anti-cancer directed receptors that could be transferred into recipient cells for active cellular immunotherapy for patients with PDAC. References Zhao Y, Niu C, Cui J. Gamma-delta (γδ) T cells: friend or foe in cancer development? J Transl Med. 2018; 16(1):3 Maeurer MJ, Martin D, Walter W, Liu K, Zitvogel L, Halusczcak K, Rabinowich H, Duquesnoy R, Storkus W, Lotze MT. Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin. J Exp Med. 1996; 183(4):1681-1696 Lo Presti E, Pizzolato G, Corsale AM, Caccamo N, Sireci G, Dieli F, Meraviglia S. γδ T cells and Tumor Microenvironment: From Immunosurveillance to Tumor Evasion. Front Immunol. 2018; 9:1395 Ethics Approval This study was approved by the Champalimaud Foundation's Ethics Committee. Research complied with the corresponding ethical principles and the applicable international, EU and national directive laws (EU Directive 2004/23/EC). Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
Related Topics
Concepts
T-cell receptor
Tumor-infiltrating lymphocytes
Cancer research
Pancreatic cancer
Tumor microenvironment
T cell
Biology
Immunotherapy
Immune system
Cancer
Immunology
Genetics
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1136/jitc-2022-sitc2022.0355
- https://jitc.bmj.com/content/jitc/10/Suppl_2/A374.full.pdf
- OA Status
- bronze
- References
- 3
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4308376182
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4308376182Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1136/jitc-2022-sitc2022.0355Digital Object Identifier
- Title
-
355 TCR γδ+ TIL from patients with pancreatic cancer recognize autologous tumor cells restricted by CD1dWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-11-01Full publication date if available
- Authors
-
Joana R. Lérias, Patrícia António, Jéssica Kamiki, Rodrigo Eduardo, Sara Cascais, Bernardo Marinheiro, Eric de Sousa, Carolina Mendonça Gorgulho, Andreia Maia, Mireia Castillo-Martín, Markus W. Buechler, Carlos Carvalho, Antonio López-Beltrán, Sam Jeong, Ridong Chen, Markus MaeurerList of authors in order
- Landing page
-
https://doi.org/10.1136/jitc-2022-sitc2022.0355Publisher landing page
- PDF URL
-
https://jitc.bmj.com/content/jitc/10/Suppl_2/A374.full.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://jitc.bmj.com/content/jitc/10/Suppl_2/A374.full.pdfDirect OA link when available
- Concepts
-
T-cell receptor, Tumor-infiltrating lymphocytes, Cancer research, Pancreatic cancer, Tumor microenvironment, T cell, Biology, Immunotherapy, Immune system, Cancer, Immunology, GeneticsTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
3Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4308376182 |
|---|---|
| doi | https://doi.org/10.1136/jitc-2022-sitc2022.0355 |
| ids.doi | https://doi.org/10.1136/jitc-2022-sitc2022.0355 |
| ids.openalex | https://openalex.org/W4308376182 |
| fwci | 0.0 |
| type | article |
| title | 355 TCR γδ+ TIL from patients with pancreatic cancer recognize autologous tumor cells restricted by CD1d |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | A374 |
| biblio.first_page | A374 |
| topics[0].id | https://openalex.org/T11491 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9994000196456909 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | CAR-T cell therapy research |
| topics[1].id | https://openalex.org/T10158 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9958999752998352 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Cancer Immunotherapy and Biomarkers |
| topics[2].id | https://openalex.org/T10580 |
| topics[2].field.id | https://openalex.org/fields/24 |
| topics[2].field.display_name | Immunology and Microbiology |
| topics[2].score | 0.989799976348877 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2403 |
| topics[2].subfield.display_name | Immunology |
| topics[2].display_name | Immunotherapy and Immune Responses |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C19317047 |
| concepts[0].level | 4 |
| concepts[0].score | 0.7307791113853455 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q412037 |
| concepts[0].display_name | T-cell receptor |
| concepts[1].id | https://openalex.org/C2778326572 |
| concepts[1].level | 4 |
| concepts[1].score | 0.6636531949043274 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q7852668 |
| concepts[1].display_name | Tumor-infiltrating lymphocytes |
| concepts[2].id | https://openalex.org/C502942594 |
| concepts[2].level | 1 |
| concepts[2].score | 0.5433351397514343 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[2].display_name | Cancer research |
| concepts[3].id | https://openalex.org/C2780210213 |
| concepts[3].level | 3 |
| concepts[3].score | 0.515617311000824 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q212961 |
| concepts[3].display_name | Pancreatic cancer |
| concepts[4].id | https://openalex.org/C2776107976 |
| concepts[4].level | 3 |
| concepts[4].score | 0.47799792885780334 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1786433 |
| concepts[4].display_name | Tumor microenvironment |
| concepts[5].id | https://openalex.org/C2776090121 |
| concepts[5].level | 3 |
| concepts[5].score | 0.4737720787525177 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q193529 |
| concepts[5].display_name | T cell |
| concepts[6].id | https://openalex.org/C86803240 |
| concepts[6].level | 0 |
| concepts[6].score | 0.46639153361320496 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[6].display_name | Biology |
| concepts[7].id | https://openalex.org/C2777701055 |
| concepts[7].level | 3 |
| concepts[7].score | 0.43766719102859497 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[7].display_name | Immunotherapy |
| concepts[8].id | https://openalex.org/C8891405 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4031250476837158 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1059 |
| concepts[8].display_name | Immune system |
| concepts[9].id | https://openalex.org/C121608353 |
| concepts[9].level | 2 |
| concepts[9].score | 0.3539058566093445 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[9].display_name | Cancer |
| concepts[10].id | https://openalex.org/C203014093 |
| concepts[10].level | 1 |
| concepts[10].score | 0.2940419316291809 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[10].display_name | Immunology |
| concepts[11].id | https://openalex.org/C54355233 |
| concepts[11].level | 1 |
| concepts[11].score | 0.0 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q7162 |
| concepts[11].display_name | Genetics |
| keywords[0].id | https://openalex.org/keywords/t-cell-receptor |
| keywords[0].score | 0.7307791113853455 |
| keywords[0].display_name | T-cell receptor |
| keywords[1].id | https://openalex.org/keywords/tumor-infiltrating-lymphocytes |
| keywords[1].score | 0.6636531949043274 |
| keywords[1].display_name | Tumor-infiltrating lymphocytes |
| keywords[2].id | https://openalex.org/keywords/cancer-research |
| keywords[2].score | 0.5433351397514343 |
| keywords[2].display_name | Cancer research |
| keywords[3].id | https://openalex.org/keywords/pancreatic-cancer |
| keywords[3].score | 0.515617311000824 |
| keywords[3].display_name | Pancreatic cancer |
| keywords[4].id | https://openalex.org/keywords/tumor-microenvironment |
| keywords[4].score | 0.47799792885780334 |
| keywords[4].display_name | Tumor microenvironment |
| keywords[5].id | https://openalex.org/keywords/t-cell |
| keywords[5].score | 0.4737720787525177 |
| keywords[5].display_name | T cell |
| keywords[6].id | https://openalex.org/keywords/biology |
| keywords[6].score | 0.46639153361320496 |
| keywords[6].display_name | Biology |
| keywords[7].id | https://openalex.org/keywords/immunotherapy |
| keywords[7].score | 0.43766719102859497 |
| keywords[7].display_name | Immunotherapy |
| keywords[8].id | https://openalex.org/keywords/immune-system |
| keywords[8].score | 0.4031250476837158 |
| keywords[8].display_name | Immune system |
| keywords[9].id | https://openalex.org/keywords/cancer |
| keywords[9].score | 0.3539058566093445 |
| keywords[9].display_name | Cancer |
| keywords[10].id | https://openalex.org/keywords/immunology |
| keywords[10].score | 0.2940419316291809 |
| keywords[10].display_name | Immunology |
| language | en |
| locations[0].id | doi:10.1136/jitc-2022-sitc2022.0355 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4363604233 |
| locations[0].source.issn | |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Regular and Young Investigator Award Abstracts |
| locations[0].source.host_organization | |
| locations[0].source.host_organization_name | |
| locations[0].source.host_organization_lineage | |
| locations[0].license | |
| locations[0].pdf_url | https://jitc.bmj.com/content/jitc/10/Suppl_2/A374.full.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | proceedings-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Regular and Young Investigator Award Abstracts |
| locations[0].landing_page_url | https://doi.org/10.1136/jitc-2022-sitc2022.0355 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5018632246 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-9874-5259 |
| authorships[0].author.display_name | Joana R. Lérias |
| authorships[0].countries | PT |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I113358080 |
| authorships[0].affiliations[0].raw_affiliation_string | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[0].institutions[0].id | https://openalex.org/I113358080 |
| authorships[0].institutions[0].ror | https://ror.org/03g001n57 |
| authorships[0].institutions[0].type | facility |
| authorships[0].institutions[0].lineage | https://openalex.org/I113358080 |
| authorships[0].institutions[0].country_code | PT |
| authorships[0].institutions[0].display_name | Champalimaud Foundation |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Joana Lerias |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[1].author.id | https://openalex.org/A5038301498 |
| authorships[1].author.orcid | https://orcid.org/0009-0005-4053-9646 |
| authorships[1].author.display_name | Patrícia António |
| authorships[1].countries | PT |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I113358080 |
| authorships[1].affiliations[0].raw_affiliation_string | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[1].institutions[0].id | https://openalex.org/I113358080 |
| authorships[1].institutions[0].ror | https://ror.org/03g001n57 |
| authorships[1].institutions[0].type | facility |
| authorships[1].institutions[0].lineage | https://openalex.org/I113358080 |
| authorships[1].institutions[0].country_code | PT |
| authorships[1].institutions[0].display_name | Champalimaud Foundation |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Patrícia António |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[2].author.id | https://openalex.org/A5017707069 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Jéssica Kamiki |
| authorships[2].countries | PT |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I113358080 |
| authorships[2].affiliations[0].raw_affiliation_string | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[2].institutions[0].id | https://openalex.org/I113358080 |
| authorships[2].institutions[0].ror | https://ror.org/03g001n57 |
| authorships[2].institutions[0].type | facility |
| authorships[2].institutions[0].lineage | https://openalex.org/I113358080 |
| authorships[2].institutions[0].country_code | PT |
| authorships[2].institutions[0].display_name | Champalimaud Foundation |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Jéssica Kamiki |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[3].author.id | https://openalex.org/A5103733323 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Rodrigo Eduardo |
| authorships[3].countries | PT |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I113358080 |
| authorships[3].affiliations[0].raw_affiliation_string | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[3].institutions[0].id | https://openalex.org/I113358080 |
| authorships[3].institutions[0].ror | https://ror.org/03g001n57 |
| authorships[3].institutions[0].type | facility |
| authorships[3].institutions[0].lineage | https://openalex.org/I113358080 |
| authorships[3].institutions[0].country_code | PT |
| authorships[3].institutions[0].display_name | Champalimaud Foundation |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Rodrigo Eduardo |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[4].author.id | https://openalex.org/A5048163207 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Sara Cascais |
| authorships[4].countries | PT |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I113358080 |
| authorships[4].affiliations[0].raw_affiliation_string | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[4].institutions[0].id | https://openalex.org/I113358080 |
| authorships[4].institutions[0].ror | https://ror.org/03g001n57 |
| authorships[4].institutions[0].type | facility |
| authorships[4].institutions[0].lineage | https://openalex.org/I113358080 |
| authorships[4].institutions[0].country_code | PT |
| authorships[4].institutions[0].display_name | Champalimaud Foundation |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Sara Cascais |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[5].author.id | https://openalex.org/A5015131107 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Bernardo Marinheiro |
| authorships[5].countries | PT |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I113358080 |
| authorships[5].affiliations[0].raw_affiliation_string | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[5].institutions[0].id | https://openalex.org/I113358080 |
| authorships[5].institutions[0].ror | https://ror.org/03g001n57 |
| authorships[5].institutions[0].type | facility |
| authorships[5].institutions[0].lineage | https://openalex.org/I113358080 |
| authorships[5].institutions[0].country_code | PT |
| authorships[5].institutions[0].display_name | Champalimaud Foundation |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Bernardo Marinheiro |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[6].author.id | https://openalex.org/A5046220787 |
| authorships[6].author.orcid | https://orcid.org/0000-0001-6582-7365 |
| authorships[6].author.display_name | Eric de Sousa |
| authorships[6].countries | PT |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I113358080 |
| authorships[6].affiliations[0].raw_affiliation_string | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[6].institutions[0].id | https://openalex.org/I113358080 |
| authorships[6].institutions[0].ror | https://ror.org/03g001n57 |
| authorships[6].institutions[0].type | facility |
| authorships[6].institutions[0].lineage | https://openalex.org/I113358080 |
| authorships[6].institutions[0].country_code | PT |
| authorships[6].institutions[0].display_name | Champalimaud Foundation |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Eric De Sousa |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[7].author.id | https://openalex.org/A5051898720 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-6569-8647 |
| authorships[7].author.display_name | Carolina Mendonça Gorgulho |
| authorships[7].countries | PT |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I113358080 |
| authorships[7].affiliations[0].raw_affiliation_string | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[7].institutions[0].id | https://openalex.org/I113358080 |
| authorships[7].institutions[0].ror | https://ror.org/03g001n57 |
| authorships[7].institutions[0].type | facility |
| authorships[7].institutions[0].lineage | https://openalex.org/I113358080 |
| authorships[7].institutions[0].country_code | PT |
| authorships[7].institutions[0].display_name | Champalimaud Foundation |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Carolina Gorgulho |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[8].author.id | https://openalex.org/A5089239728 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-7860-6219 |
| authorships[8].author.display_name | Andreia Maia |
| authorships[8].countries | PT |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I113358080 |
| authorships[8].affiliations[0].raw_affiliation_string | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[8].institutions[0].id | https://openalex.org/I113358080 |
| authorships[8].institutions[0].ror | https://ror.org/03g001n57 |
| authorships[8].institutions[0].type | facility |
| authorships[8].institutions[0].lineage | https://openalex.org/I113358080 |
| authorships[8].institutions[0].country_code | PT |
| authorships[8].institutions[0].display_name | Champalimaud Foundation |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Andreia Maia |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[9].author.id | https://openalex.org/A5085458716 |
| authorships[9].author.orcid | https://orcid.org/0000-0001-8926-6013 |
| authorships[9].author.display_name | Mireia Castillo-Martín |
| authorships[9].countries | PT |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I113358080 |
| authorships[9].affiliations[0].raw_affiliation_string | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[9].institutions[0].id | https://openalex.org/I113358080 |
| authorships[9].institutions[0].ror | https://ror.org/03g001n57 |
| authorships[9].institutions[0].type | facility |
| authorships[9].institutions[0].lineage | https://openalex.org/I113358080 |
| authorships[9].institutions[0].country_code | PT |
| authorships[9].institutions[0].display_name | Champalimaud Foundation |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Mireia Castillo-Martin |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[10].author.id | https://openalex.org/A5111679335 |
| authorships[10].author.orcid | |
| authorships[10].author.display_name | Markus W. Buechler |
| authorships[10].countries | PT |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I113358080 |
| authorships[10].affiliations[0].raw_affiliation_string | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[10].institutions[0].id | https://openalex.org/I113358080 |
| authorships[10].institutions[0].ror | https://ror.org/03g001n57 |
| authorships[10].institutions[0].type | facility |
| authorships[10].institutions[0].lineage | https://openalex.org/I113358080 |
| authorships[10].institutions[0].country_code | PT |
| authorships[10].institutions[0].display_name | Champalimaud Foundation |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Markus Buechler |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[11].author.id | https://openalex.org/A5015800782 |
| authorships[11].author.orcid | https://orcid.org/0000-0003-4944-3075 |
| authorships[11].author.display_name | Carlos Carvalho |
| authorships[11].countries | PT |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I113358080 |
| authorships[11].affiliations[0].raw_affiliation_string | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[11].institutions[0].id | https://openalex.org/I113358080 |
| authorships[11].institutions[0].ror | https://ror.org/03g001n57 |
| authorships[11].institutions[0].type | facility |
| authorships[11].institutions[0].lineage | https://openalex.org/I113358080 |
| authorships[11].institutions[0].country_code | PT |
| authorships[11].institutions[0].display_name | Champalimaud Foundation |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Carlos Carvalho |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[12].author.id | https://openalex.org/A5035937813 |
| authorships[12].author.orcid | https://orcid.org/0000-0002-0724-1267 |
| authorships[12].author.display_name | Antonio López-Beltrán |
| authorships[12].countries | PT |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I113358080 |
| authorships[12].affiliations[0].raw_affiliation_string | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[12].institutions[0].id | https://openalex.org/I113358080 |
| authorships[12].institutions[0].ror | https://ror.org/03g001n57 |
| authorships[12].institutions[0].type | facility |
| authorships[12].institutions[0].lineage | https://openalex.org/I113358080 |
| authorships[12].institutions[0].country_code | PT |
| authorships[12].institutions[0].display_name | Champalimaud Foundation |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Antonio Beltran |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[13].author.id | https://openalex.org/A5088568882 |
| authorships[13].author.orcid | |
| authorships[13].author.display_name | Sam Jeong |
| authorships[13].affiliations[0].raw_affiliation_string | Human Cell Inc, Naperville, IL, USA |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Sam Jeong |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Human Cell Inc, Naperville, IL, USA |
| authorships[14].author.id | https://openalex.org/A5002981147 |
| authorships[14].author.orcid | https://orcid.org/0000-0001-9323-2000 |
| authorships[14].author.display_name | Ridong Chen |
| authorships[14].affiliations[0].raw_affiliation_string | Human Cell Inc, Naperville, IL, USA |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Ridong Chen |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Human Cell Inc, Naperville, IL, USA |
| authorships[15].author.id | https://openalex.org/A5006698445 |
| authorships[15].author.orcid | https://orcid.org/0000-0002-8436-8077 |
| authorships[15].author.display_name | Markus Maeurer |
| authorships[15].countries | PT |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I113358080 |
| authorships[15].affiliations[0].raw_affiliation_string | Champalimaud Center for the Unknown, Lisbon, Portugal |
| authorships[15].institutions[0].id | https://openalex.org/I113358080 |
| authorships[15].institutions[0].ror | https://ror.org/03g001n57 |
| authorships[15].institutions[0].type | facility |
| authorships[15].institutions[0].lineage | https://openalex.org/I113358080 |
| authorships[15].institutions[0].country_code | PT |
| authorships[15].institutions[0].display_name | Champalimaud Foundation |
| authorships[15].author_position | last |
| authorships[15].raw_author_name | Markus Maeurer |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Champalimaud Center for the Unknown, Lisbon, Portugal |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://jitc.bmj.com/content/jitc/10/Suppl_2/A374.full.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | 355 TCR γδ+ TIL from patients with pancreatic cancer recognize autologous tumor cells restricted by CD1d |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11491 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9994000196456909 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | CAR-T cell therapy research |
| related_works | https://openalex.org/W2394822632, https://openalex.org/W1996773663, https://openalex.org/W4200022043, https://openalex.org/W2112727616, https://openalex.org/W2884525857, https://openalex.org/W4322720888, https://openalex.org/W3010386727, https://openalex.org/W4296613612, https://openalex.org/W3193904228, https://openalex.org/W2412744492 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1136/jitc-2022-sitc2022.0355 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4363604233 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Regular and Young Investigator Award Abstracts |
| best_oa_location.source.host_organization | |
| best_oa_location.source.host_organization_name | |
| best_oa_location.source.host_organization_lineage | |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://jitc.bmj.com/content/jitc/10/Suppl_2/A374.full.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | proceedings-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Regular and Young Investigator Award Abstracts |
| best_oa_location.landing_page_url | https://doi.org/10.1136/jitc-2022-sitc2022.0355 |
| primary_location.id | doi:10.1136/jitc-2022-sitc2022.0355 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4363604233 |
| primary_location.source.issn | |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Regular and Young Investigator Award Abstracts |
| primary_location.source.host_organization | |
| primary_location.source.host_organization_name | |
| primary_location.source.host_organization_lineage | |
| primary_location.license | |
| primary_location.pdf_url | https://jitc.bmj.com/content/jitc/10/Suppl_2/A374.full.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | proceedings-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Regular and Young Investigator Award Abstracts |
| primary_location.landing_page_url | https://doi.org/10.1136/jitc-2022-sitc2022.0355 |
| publication_date | 2022-11-01 |
| publication_year | 2022 |
| referenced_works | https://openalex.org/W6600140940, https://openalex.org/W2116689616, https://openalex.org/W2784311950 |
| referenced_works_count | 3 |
| abstract_inverted_index.A | 540 |
| abstract_inverted_index.I | 49 |
| abstract_inverted_index.T | 413, 477 |
| abstract_inverted_index.a | 25, 57, 228, 238, 352 |
| abstract_inverted_index.C, | 408 |
| abstract_inverted_index.D, | 429 |
| abstract_inverted_index.E, | 463 |
| abstract_inverted_index.EU | 514 |
| abstract_inverted_index.F, | 473 |
| abstract_inverted_index.G, | 465, 471 |
| abstract_inverted_index.H, | 439 |
| abstract_inverted_index.J. | 410 |
| abstract_inverted_index.K, | 433, 437 |
| abstract_inverted_index.L, | 435 |
| abstract_inverted_index.Lo | 461 |
| abstract_inverted_index.N, | 469 |
| abstract_inverted_index.R, | 441 |
| abstract_inverted_index.S. | 475 |
| abstract_inverted_index.W, | 431, 443 |
| abstract_inverted_index.Y, | 406 |
| abstract_inverted_index.an | 135, 270, 291 |
| abstract_inverted_index.as | 69, 165, 383 |
| abstract_inverted_index.be | 83, 381, 391 |
| abstract_inverted_index.by | 46, 73, 113, 150, 194, 199, 232, 265, 318, 368, 497, 550 |
| abstract_inverted_index.in | 132, 187, 208, 227, 345, 418 |
| abstract_inverted_index.is | 3, 546 |
| abstract_inverted_index.of | 8, 78, 95, 102, 253, 277, 284, 302, 315, 334, 341, 347, 356, 453, 533, 542, 553 |
| abstract_inverted_index.on | 92 |
| abstract_inverted_index.or | 72, 416 |
| abstract_inverted_index.to | 127, 484 |
| abstract_inverted_index.(EU | 519 |
| abstract_inverted_index.2-3 | 140 |
| abstract_inverted_index.7th | 5 |
| abstract_inverted_index.AM, | 467 |
| abstract_inverted_index.Cui | 409 |
| abstract_inverted_index.Exp | 457 |
| abstract_inverted_index.Liu | 432 |
| abstract_inverted_index.MHC | 48, 372 |
| abstract_inverted_index.MJ, | 427 |
| abstract_inverted_index.MT. | 445 |
| abstract_inverted_index.Niu | 407 |
| abstract_inverted_index.TCR | 98, 103, 182, 189, 195, 210, 235, 240, 293 |
| abstract_inverted_index.TIL | 96, 110, 129, 289, 343, 357 |
| abstract_inverted_index.The | 89 |
| abstract_inverted_index.and | 38, 61, 106, 145, 153, 163, 201, 222, 245, 260, 279, 287, 299, 304, 310, 327, 339, 370, 376, 479, 510, 515, 536 |
| abstract_inverted_index.any | 537 |
| abstract_inverted_index.are | 14, 53 |
| abstract_inverted_index.can | 380 |
| abstract_inverted_index.foe | 417 |
| abstract_inverted_index.for | 28, 65, 139, 358, 385, 396, 400, 531, 548 |
| abstract_inverted_index.the | 4, 75, 93, 166, 251, 498, 506, 511, 529, 543, 551 |
| abstract_inverted_index.was | 125, 172, 185, 197, 495, 526 |
| abstract_inverted_index.– | 214, 219 |
| abstract_inverted_index.<i>J | 421, 456 |
| abstract_inverted_index.CD1d | 278, 312, 374 |
| abstract_inverted_index.From | 482 |
| abstract_inverted_index.PDAC | 29, 33, 285, 361 |
| abstract_inverted_index.TCRs | 80, 379 |
| abstract_inverted_index.TIL. | 191 |
| abstract_inverted_index.TILs | 31, 52 |
| abstract_inverted_index.This | 350, 493 |
| abstract_inverted_index.Zhao | 405 |
| abstract_inverted_index.copy | 541 |
| abstract_inverted_index.deep | 183 |
| abstract_inverted_index.flow | 151 |
| abstract_inverted_index.from | 32, 178, 528 |
| abstract_inverted_index.into | 85, 393 |
| abstract_inverted_index.laws | 518 |
| abstract_inverted_index.mAbs | 162 |
| abstract_inverted_index.mRNA | 298 |
| abstract_inverted_index.more | 58 |
| abstract_inverted_index.that | 41, 81, 362, 389 |
| abstract_inverted_index.this | 534, 554 |
| abstract_inverted_index.upon | 116 |
| abstract_inverted_index.used | 126, 382 |
| abstract_inverted_index.were | 148, 158 |
| abstract_inverted_index.will | 35 |
| abstract_inverted_index.with | 56, 134, 242, 269, 360, 402, 505 |
| abstract_inverted_index.γδ | 378, 476 |
| abstract_inverted_index.(TIL) | 23 |
| abstract_inverted_index.1996; | 459 |
| abstract_inverted_index.2018; | 424, 489 |
| abstract_inverted_index.CXCL9 | 303 |
| abstract_inverted_index.Dieli | 472 |
| abstract_inverted_index.Human | 446 |
| abstract_inverted_index.Lotze | 444 |
| abstract_inverted_index.NRLP3 | 117, 136, 205, 248, 271, 295, 322 |
| abstract_inverted_index.PDAC. | 403 |
| abstract_inverted_index.TILs, | 331 |
| abstract_inverted_index.Tumor | 192, 480, 485 |
| abstract_inverted_index.after | 215 |
| abstract_inverted_index.cause | 7 |
| abstract_inverted_index.cells | 44, 212, 226, 259, 395, 452, 478 |
| abstract_inverted_index.could | 82, 390 |
| abstract_inverted_index.exome | 180 |
| abstract_inverted_index.still | 15 |
| abstract_inverted_index.study | 90, 494 |
| abstract_inverted_index.tumor | 20, 43, 123, 155, 179, 258, 364, 451 |
| abstract_inverted_index.using | 19, 130, 160, 174 |
| abstract_inverted_index.which | 213, 306 |
| abstract_inverted_index.αβ+ | 37, 254 |
| abstract_inverted_index.γδ+ | 39, 51, 104, 142, 190, 196, 211, 281, 319, 342 |
| abstract_inverted_index.(γδ) | 412 |
| abstract_inverted_index.Editor | 552 |
| abstract_inverted_index.Ethics | 501 |
| abstract_inverted_index.Martin | 428 |
| abstract_inverted_index.Presti | 462 |
| abstract_inverted_index.Sireci | 470 |
| abstract_inverted_index.T-cell | 143, 146 |
| abstract_inverted_index.Transl | 422 |
| abstract_inverted_index.Walter | 430 |
| abstract_inverted_index.active | 397 |
| abstract_inverted_index.allows | 351 |
| abstract_inverted_index.assays | 157 |
| abstract_inverted_index.cancer | 2, 225, 419 |
| abstract_inverted_index.cells, | 105 |
| abstract_inverted_index.cells. | 88 |
| abstract_inverted_index.cells: | 414 |
| abstract_inverted_index.deaths | 10 |
| abstract_inverted_index.friend | 415 |
| abstract_inverted_index.gauged | 198 |
| abstract_inverted_index.immune | 87 |
| abstract_inverted_index.mutant | 261, 328 |
| abstract_inverted_index.option | 27 |
| abstract_inverted_index.review | 549 |
| abstract_inverted_index.sorted | 188 |
| abstract_inverted_index.target | 262 |
| abstract_inverted_index.tested | 149 |
| abstract_inverted_index.tissue | 124, 286, 308, 337 |
| abstract_inverted_index.usage. | 247 |
| abstract_inverted_index.viable | 26 |
| abstract_inverted_index.weeks. | 141 |
| abstract_inverted_index.γδ+, | 99 |
| abstract_inverted_index.CXCL10, | 305 |
| abstract_inverted_index.Caccamo | 468 |
| abstract_inverted_index.Corsale | 466 |
| abstract_inverted_index.Freshly | 121 |
| abstract_inverted_index.Maeurer | 426 |
| abstract_inverted_index.Spatial | 273 |
| abstract_inverted_index.Storkus | 442 |
| abstract_inverted_index.T-cells | 255 |
| abstract_inverted_index.Vgamma3 | 244 |
| abstract_inverted_index.Vgamma8 | 246 |
| abstract_inverted_index.Written | 523 |
| abstract_inverted_index.against | 256 |
| abstract_inverted_index.cloning | 74 |
| abstract_inverted_index.consent | 525, 545 |
| abstract_inverted_index.damaged | 316, 348 |
| abstract_inverted_index.defined | 112, 231, 264 |
| abstract_inverted_index.derived | 177 |
| abstract_inverted_index.engaged | 344 |
| abstract_inverted_index.epitope | 329 |
| abstract_inverted_index.ethical | 508 |
| abstract_inverted_index.fashion | 230 |
| abstract_inverted_index.favored | 311 |
| abstract_inverted_index.focused | 91, 239 |
| abstract_inverted_index.images. | 539 |
| abstract_inverted_index.include | 36 |
| abstract_inverted_index.leading | 6 |
| abstract_inverted_index.lesions | 34 |
| abstract_inverted_index.options | 13 |
| abstract_inverted_index.origin. | 455 |
| abstract_inverted_index.pathway | 118, 137, 323 |
| abstract_inverted_index.patient | 530 |
| abstract_inverted_index.present | 62 |
| abstract_inverted_index.protein | 300 |
| abstract_inverted_index.purity) | 218 |
| abstract_inverted_index.results | 207 |
| abstract_inverted_index.sorting | 216 |
| abstract_inverted_index.spatial | 202 |
| abstract_inverted_index.testing | 107 |
| abstract_inverted_index.therapy | 68 |
| abstract_inverted_index.unusual | 243 |
| abstract_inverted_index.written | 544 |
| abstract_inverted_index.(>90% | 217 |
| abstract_inverted_index.<i>Front | 487 |
| abstract_inverted_index.Evasion. | 486 |
| abstract_inverted_index.Med</i>. | 423, 458 |
| abstract_inverted_index.Research | 503 |
| abstract_inverted_index.T-cells, | 40 |
| abstract_inverted_index.T-cells. | 320 |
| abstract_inverted_index.T-cells; | 282 |
| abstract_inverted_index.Vdelta1+ | 448 |
| abstract_inverted_index.Zitvogel | 434 |
| abstract_inverted_index.abstract | 535 |
| abstract_inverted_index.adoptive | 66 |
| abstract_inverted_index.analysis | 101, 171 |
| abstract_inverted_index.antigens | 366 |
| abstract_inverted_index.approved | 496 |
| abstract_inverted_index.blocking | 161 |
| abstract_inverted_index.cellular | 67, 70, 398 |
| abstract_inverted_index.complied | 504 |
| abstract_inverted_index.directed | 109, 387 |
| abstract_inverted_index.epitopes | 263 |
| abstract_inverted_index.informed | 524 |
| abstract_inverted_index.invasion | 309, 338 |
| abstract_inverted_index.journal. | 555 |
| abstract_inverted_index.limited; | 16 |
| abstract_inverted_index.national | 516 |
| abstract_inverted_index.obtained | 527 |
| abstract_inverted_index.patients | 359, 401 |
| abstract_inverted_index.peptides | 176 |
| abstract_inverted_index.readout; | 168 |
| abstract_inverted_index.relevant | 354 |
| abstract_inverted_index.revealed | 237, 275 |
| abstract_inverted_index.specific | 330 |
| abstract_inverted_index.Directive | 520 |
| abstract_inverted_index.Duquesnoy | 440 |
| abstract_inverted_index.IFN-gamma | 114, 164, 233, 266 |
| abstract_inverted_index.Pizzolato | 464 |
| abstract_inverted_index.Treatment | 12 |
| abstract_inverted_index.abrogated | 268 |
| abstract_inverted_index.activator | 138 |
| abstract_inverted_index.available | 547 |
| abstract_inverted_index.blueprint | 77 |
| abstract_inverted_index.classical | 369 |
| abstract_inverted_index.cytokines | 131 |
| abstract_inverted_index.cytometry | 152 |
| abstract_inverted_index.directive | 517 |
| abstract_inverted_index.exhibited | 290 |
| abstract_inverted_index.expansion | 94, 144, 340, 355 |
| abstract_inverted_index.favorable | 59 |
| abstract_inverted_index.frequency | 252 |
| abstract_inverted_index.generally | 54 |
| abstract_inverted_index.harvested | 122 |
| abstract_inverted_index.increased | 209, 250, 297, 325, 332 |
| abstract_inverted_index.molecular | 76, 100, 169 |
| abstract_inverted_index.patients. | 30 |
| abstract_inverted_index.performed | 159, 173, 186 |
| abstract_inverted_index.products, | 71 |
| abstract_inverted_index.promising | 63 |
| abstract_inverted_index.propagate | 128 |
| abstract_inverted_index.receptors | 388 |
| abstract_inverted_index.recipient | 86, 394 |
| abstract_inverted_index.recognize | 42, 450 |
| abstract_inverted_index.represent | 24 |
| abstract_inverted_index.synthetic | 175 |
| abstract_inverted_index.<h3>Ethics | 491 |
| abstract_inverted_index.Committee. | 502 |
| abstract_inverted_index.Halusczcak | 436 |
| abstract_inverted_index.Meraviglia | 474 |
| abstract_inverted_index.Pancreatic | 1 |
| abstract_inverted_index.Rabinowich | 438 |
| abstract_inverted_index.allogeneic | 223 |
| abstract_inverted_index.anti-tumor | 108 |
| abstract_inverted_index.applicable | 512 |
| abstract_inverted_index.approaches | 18 |
| abstract_inverted_index.associated | 55, 365 |
| abstract_inverted_index.autologous | 154, 221, 257 |
| abstract_inverted_index.biological | 167 |
| abstract_inverted_index.blueprints | 384 |
| abstract_inverted_index.candidates | 64 |
| abstract_inverted_index.chemokines | 335 |
| abstract_inverted_index.clinically | 353 |
| abstract_inverted_index.containing | 97 |
| abstract_inverted_index.epithelial | 454 |
| abstract_inverted_index.expression | 301, 333 |
| abstract_inverted_index.inhibitor. | 272 |
| abstract_inverted_index.intestinal | 447 |
| abstract_inverted_index.molecules. | 373 |
| abstract_inverted_index.pancreatic | 224 |
| abstract_inverted_index.principles | 509 |
| abstract_inverted_index.production | 115 |
| abstract_inverted_index.recognized | 220, 363 |
| abstract_inverted_index.repertoire | 241 |
| abstract_inverted_index.restricted | 45, 313, 367, 375 |
| abstract_inverted_index.sequencing | 184, 236 |
| abstract_inverted_index.worldwide. | 11 |
| abstract_inverted_index.Gamma-delta | 411 |
| abstract_inverted_index.anti-cancer | 386 |
| abstract_inverted_index.combination | 133 |
| abstract_inverted_index.facilitates | 307 |
| abstract_inverted_index.lymphocytes | 22, 449 |
| abstract_inverted_index.oligoclonal | 292 |
| abstract_inverted_index.production, | 267 |
| abstract_inverted_index.production. | 234 |
| abstract_inverted_index.publication | 532 |
| abstract_inverted_index.recognition | 156, 170, 314 |
| abstract_inverted_index.repertoire. | 294 |
| abstract_inverted_index.sequencing. | 181 |
| abstract_inverted_index.specificity | 111 |
| abstract_inverted_index.stimulation | 206, 249, 296, 324 |
| abstract_inverted_index.transferred | 84, 392 |
| abstract_inverted_index.2004/23/EC). | 521 |
| abstract_inverted_index.Champalimaud | 499 |
| abstract_inverted_index.Foundation's | 500 |
| abstract_inverted_index.Immunol</i>. | 488 |
| abstract_inverted_index.accompanying | 538 |
| abstract_inverted_index.development? | 420 |
| abstract_inverted_index.facilitating | 336 |
| abstract_inverted_index.infiltrating | 21 |
| abstract_inverted_index.infiltration | 193 |
| abstract_inverted_index.mitochondria | 317 |
| abstract_inverted_index.stimulation. | 119 |
| abstract_inverted_index.surveillance | 346 |
| abstract_inverted_index.<b>9</b>:1395 | 490 |
| abstract_inverted_index.Approval</h3> | 492 |
| abstract_inverted_index.corresponding | 288, 507 |
| abstract_inverted_index.immunotherapy | 399 |
| abstract_inverted_index.mitochondria. | 349 |
| abstract_inverted_index.non-classical | 47, 371 |
| abstract_inverted_index.<b>16</b>(1):3 | 425 |
| abstract_inverted_index.TCR-sequencing | 283 |
| abstract_inverted_index.cancer-related | 9 |
| abstract_inverted_index.international, | 513 |
| abstract_inverted_index.tumor-reactive | 326, 377 |
| abstract_inverted_index.CD1d-restricted | 229 |
| abstract_inverted_index.cancer-specific | 79 |
| abstract_inverted_index.co-localization | 276 |
| abstract_inverted_index.transcriptomics | 274 |
| abstract_inverted_index.<h3>Consent</h3> | 522 |
| abstract_inverted_index.<h3>Methods</h3> | 120 |
| abstract_inverted_index.<h3>Results</h3> | 204 |
| abstract_inverted_index.transcriptomics. | 203 |
| abstract_inverted_index.Microenvironment: | 481 |
| abstract_inverted_index.immunotherapeutic | 17 |
| abstract_inverted_index.Immunosurveillance | 483 |
| abstract_inverted_index.<h3>Background</h3> | 0 |
| abstract_inverted_index.<h3>References</h3> | 404 |
| abstract_inverted_index.<h3>Conclusions</h3> | 321 |
| abstract_inverted_index.immunohistochemistry | 200 |
| abstract_inverted_index.activation/exhaustion | 147 |
| abstract_inverted_index.prognosis<sup>3</sup> | 60 |
| abstract_inverted_index.<b>183</b>(4):1681-1696 | 460 |
| abstract_inverted_index.molecules.<sup>1,2</sup> | 50 |
| abstract_inverted_index.perforin+granzymeA+granzymeB | 280 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 16 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8700000047683716 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.23498867 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |